Wu D, Guo X, Su J, Chen R, Berenzon D, Guthold M, Bonin K, Zhao W, Zhou X. CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathway. Biochim Biophys Acta. 2015;1853(2):338-347.
Ahmed T, Holwerda S, Klepin HD, Isom S, Ellis LR, Lyerly S, Manuel M, Dralle S, Berenzon D, Powell BL, Pardee TS. High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly. Leuk Res. 2015;39(9):945-949.
Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK, Abboud CN, Adler K, Heaney ML, Jabbour EJ, Komrokji RS, Moliterno AR, Ritchie EK, Rice L, Mascarenhas J, Hoffman R. Polycythemia vera: an appraisal of the biology and management 10 years after the discovery of JAK2 V617F. J Clin Oncol. 2015;():.
Pardee TS, Stadelman K, Isom S, Ellis LR, Berenzon D, Hurd DD, Howard DS, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL. Activity of the mitochondrial metabolism inhibitor cpi-613 in combination with high dose Ara-C (HDAC) and mitoxantrone in high risk relapsed or refractory acute myeloid leukemia (AML) [abstract]. J Clin Oncol. 2015;33(15 Suppl):7015.
Tawfik B, Sliesoraitis S, Lyerly S, Klepin HD, Lawrence J, Isom S, Ellis LR, Manuel M, Dralle S, Berenzon D, Powell BL, Pardee T. Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML). Ann Hematol. 2014;93(1):47-55.
Pardee TS, Stadelman K, Isom S, Ellis LR, Berenzon D, Hurd DD, Harrelson R, Manuel M, Dralle S, Lyerly S [sic] [Lyerly ES], Powell BL. The mitochondrial metabolism inhibitor Cpi-613 is highly active in combination with high dose Ara-C (HiDAC) and mitoxantrone in a phase I study for relapsed or refractory acute myeloid leukemia (AML). Blood. 2014;124(21):3744.
Chaurasia P, Berenzon D, Hoffman R. Chromatin-modifying agents promote the ex vivo production of functional human erythroid progenitor cells. Blood. 2011;117(17):4632-4641.
Chaurasin P, Berenzon D, Hoffman R. Chromatin modifying agents promote the ex vivo production of functional human erythroid progenitor cells [abstract]. Blood. 2010;116(21):154.
For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.
For a list of earlier publications, visit the Carpenter Library Publication Search.
Assistant Professor, Hematology & Oncology
Acute and Chronic Leukemia, Essential Thrombocythemia, Hematologic Malignancies, Multiple Myeloma, Polycythemia Vera, Primary Myelofibrosis
The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.
Dr. had reviewed my chart and history very thoroughly. He spent a great deal of time explaining the disorder they were checking for and reassuring me. He emailed after the test to say it was as he had suspected and I had no worries at this time. His email made me smile!
Real courtesy and concern in a difficult time.
He's a brilliant doctor.
I would recommend Dr. Berenzon and Dr. Holland to any of my family or friends
*Dr. Berenzon is informative and helpful.
very friendly and professional
Everyone was extremely caring and professional, everyone.
*Dr. Berenzon is very good in all respects.
Could not ask for a better caring doctor. Showed great care and concern abut my condition.
Lots of faith that *Dr. B. will be able to dx condition.